Extract to table

1(a), Veridian's response to the DMC findings — including its implementation of the enrollment suspension and dose modification — must also be evaluated under Section 5

2(a) conditions Penterra's obligation to close on the accuracy of the Sellers' representations and warranties as of the Closing Date (with the accuracy of the representations and warranties qualified by a Material Adverse Effect standard, except for certain fundamental representations that must be true and correct in all respects)

2(b)), or the covenant compliance closing condition (which requires that Veridian and the Sellers shall have performed and complied in all material respects with their covenants and obligations under the SPA)

1(b) The completeness of Veridian's notification must be evaluated under the specific requirements of Section 5

But the underlying data that prompted the recommendation — the CRS incidence rates, the treatment-related death count, and the ORR data — are equally material and must be disclosed to satisfy the notification obligation

The covenant compliance closing condition in the SPA requires that Veridian and the Sellers shall have performed and complied in all material respects with their covenants and obligations under the SPA as a condition to Penterra's obligation to close